ascopubs.org

A randomized, double-blinded, phase III study of icaritin versus huachashu as the first-line therapy in biomarker-enriched HBV-related advanced hepatocellular carcinoma with ...

Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC). This is an ASCO ...
ascopubs.org

Survival and safety outcomes of first-line immune checkpoint inhibitor combinations versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A meta-analysis.

Locoregional therapy for hepatocellular carcinoma before transplant: Impact on tumor necrosis, tumor recurrence, and long-term survival. This is an ASCO Meeting Abstract from the 2026 ASCO ...